Second, we have not compared the TIL’s expansion yield, anti-tumor efficacy, clones’ diversities, exhaustion status by using T cell activator CD3/CD28 beads vs. anti-CD137 agonist antibody protocol. The gene discussed is TNFRSF9; the disease is neoplasm.